Marriott International Inc vs Viatris Inc — how do they compare? Marriott International Inc trades at $365.05 (market cap $94.16B), while Viatris Inc trades at $17.58 (market cap $20.03B). The key difference: Marriott International Inc is far larger — about 4.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and Viatris Inc for 57 Days on average.
| MAR | VTRS | |
|---|---|---|
Market Cap | $94.16B | $20.03B |
Volume | 996,176 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $18.27 |
52-Week Low | $259.04 | $9.74 |
Typical Hold Time | 164 Days | 57 Days |
Enterprise Value | $111.47B | $32.15B |
Dividend Yield | 0.81% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $363.49, up 1.96% today, showing strong momentum near resistance at $364. The stock maintains a bullish technical outlook with positive moving averages and ADX signals. Fundamentally, revenue grew to $26.19B in 2025 with a 9.62% net margin, though valuation metrics appear elevated with a P/E of 37.38. Recent earnings beat expectations in Q1 and Q2 2026, while analysts maintain a consensus price target of $386.71 with 44% buy ratings.
Outlook remains positive driven by travel demand recovery and strategic partnerships, but risks include rising debt levels (debt-to-asset ratio at 58.83% in 2025) and economic sensitivity. The stock offers moderate upside to analyst targets with institutional confidence, though high valuation requires sustained earnings growth to justify current levels.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →